“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet ...

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday that its FDA-approved anti-inflammatory agent Cosentyx failed to reach ...